Xenon Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team. We are pleased to welcome Xenon Pharmaceuticals to kick off our first day of the conference. And speaking on behalf of the company, we have CEO, Ian Mortimer. Before I turn it over to Ian, I just wanted to highlight the Q&A. There is a -- there will be a Q&A coming up here. There is an Ask A Question for those folks listening on the webcast, and I'm happy to ask the question on your behalf.
So with that, Ian, over to you.
Thanks, Tess, and good morning, everyone. Great to be here and great to kick off JPMorgan, first thing on a Monday morning. Tremendous amount of progress at Xenon over the last 12 months, so we'll review some of that, and then we'll also review the milestones going
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |